We help establish benefit and drive therapeutic value for our clients’ development-stage assets: compounds, portfolios and platforms

Defined Health has three core lines of business


Rare Disorders and Advanced Therapeutics

Our Insights

Defined Health / CH BioConsulting

Cello Health Consulting, Biotech Expansion Fueled by Defined Health

Over the course of 2018, Defined Health and Cello Health Consulting will move to a single unified brand for the global consulting business for which Defined Health will be a vital engine for growth, especially in the biotech sector. The experience and talents of Cello both complement and extend those of Defined Health, particularly in terms of more downstream commercial thinking that marries well with Defined Health’s scientific and strategic depth. This synergy is compelling, especially as an increased focus on smaller, more well-defined patient populations offers more biotechs a realistic option to go to market on their own. Most significantly, increasingly rapid approval pathways available for breakthrough therapies mean the progression from early to late stage can be quicker, sometimes a lot quicker, than in the past. We believe this is a fundamental change with very important implications even for companies just approaching the clinic.

Fresh Thinking


Clients In The News

Our Collaborators